bismuth chewables tablet (chewable)
juno otc inc - bismuth subsalicylate - tablet (chewable) - 262mg - bismuth subsalicylate 262mg - antacids and adsorbents
bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsule
par pharmaceutical, inc. - bismuth subcitrate potassium (unii: r3o80h60kx) (bismuth cation - unii:zs9cd1i8ye), metronidazole (unii: 140qmo216e) (metronidazole - unii:140qmo216e), tetracycline hydrochloride (unii: p6r62377kv) (tetracycline - unii:f8vb5m810t) - bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules in combination with omeprazole are indicated for the treatment of patients with helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate h. pylori . the eradication of helicobacter pylori has been shown to reduce the risk of duodenal ulcer recurrence. to reduce the development of drug-resistant bacteria and maintain the effectiveness of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules and other antibacterial drugs, bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules should be used to treat only indicated infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may
bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride capsule
ingenus pharmaceuticals, llc - bismuth subcitrate potassium (unii: r3o80h60kx) (bismuth cation - unii:zs9cd1i8ye), metronidazole (unii: 140qmo216e) (metronidazole - unii:140qmo216e), tetracycline hydrochloride (unii: p6r62377kv) (tetracycline - unii:f8vb5m810t) - bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules in combination with omeprazole are indicated for the treatment of patients with helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate h. pylori . the eradication of helicobacter pylori has been shown to reduce the risk of duodenal ulcer recurrence. to reduce the development of drug-resistant bacteria and maintain the effectiveness of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules and other antibacterial drugs, bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules should be used to treat only indicated infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may
bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride capsule
h2-pharma, llc - bismuth subcitrate potassium (unii: r3o80h60kx) (bismuth cation - unii:zs9cd1i8ye), metronidazole (unii: 140qmo216e) (metronidazole - unii:140qmo216e), tetracycline hydrochloride (unii: p6r62377kv) (tetracycline - unii:f8vb5m810t) - bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules in combination with omeprazole are indicated for the treatment of patients with helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate h. pylori . the eradication of helicobacter pylori has been shown to reduce the risk of duodenal ulcer recurrence. to reduce the development of drug-resistant bacteria and maintain the effectiveness of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules and other antibacterial drugs, bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules should be used to treat only indicated infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may
bismuth subgallate bp
psm healthcare ltd trading as api consumer brands - bismuth subgallate 100% - powder for oral solution - 100 % - active: bismuth subgallate 100%
pylera (bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride- 140 mg/125 mg/125 mg capsule
physicians total care, inc. - bismuth subcitrate potassium (unii: r3o80h60kx) (bismuth - unii:u015tt5i8h), metronidazole (unii: 140qmo216e) (metronidazole - unii:140qmo216e), tetracycline hydrochloride (unii: p6r62377kv) (tetracycline - unii:f8vb5m810t) - bismuth subcitrate potassium 140 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of pylera and other antibacterial drugs, pylera should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. pylera in combination with omeprazole are indicated for the treatment of patients with helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate h. pylori . the eradication of helicobacter pylori has been shown to reduce the risk of duodenal ulcer recurrence. do not administer methoxyflurane to patients taking pylera. the concurrent use of tetracycline hydrochloride, a component of pylera, with methoxyflurane has been reported to resu
bismuth subnitrate 20% / iodoform 40% paste impregnated gauze dressing 1.25cm x 200cm
martindale pharmaceuticals ltd - bismuth subnitrate; iodoform - impregnated dressing - 200mg/1gram ; 400mg/1gram
bismuth subnitrate 20% / iodoform 40% paste impregnated gauze dressing 1.25cm x 300cm
martindale pharmaceuticals ltd - bismuth subnitrate; iodoform - impregnated dressing - 200mg/1gram ; 400mg/1gram
bismuth subnitrate 20% / iodoform 40% paste impregnated gauze dressing 2.5cm x 300cm
martindale pharmaceuticals ltd - bismuth subnitrate; iodoform - impregnated dressing - 200mg/1gram ; 400mg/1gram
bismuth subsalicylate/metronidazole/tetracycline hydrochloride- bismuth subsalicylate chewable tablets/metronidazole tablets/tet
ailex pharmaceuticals, llc - bismuth subsalicylate (unii: 62tey51rr1) (salicylic acid - unii:o414pz4lpz) - the components of bismuth subsalicylate chewable tablets/ metronidazole tablets/tetracycline hydrochloride capsules (bismuth subsalicylate, metronidazole, and tetracycline hydrochloride), in combination with an h2 antagonist, are indicated for the eradication of h. pylori for treatment of patients with h. pylori infection and duodenal ulcer disease (active or a history of duodenal ulcer). the eradication of h. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence in patients with active duodenal ulcer disease (see clinical studies and dosage and administration ). to reduce the development of drug-resistant bacteria and maintain the effectiveness of bismuth subsalicylate chewable tablets/metronidazole tablets/tetracycline hydrochloride capsules and other antibacterial drugs, bismuth subsalicylate chewable tablets/metronidazole tablets/tetracycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptib